Number and percentages of patients receiving the evidence-based target dose of pharmacological treatments for CHF
| PREFER BL | PREFER EOS | Change % | p value | Control BL | Control EOS | Change % | p value | |
|---|---|---|---|---|---|---|---|---|
| Number of patients | 36 | 31 | 36 | 33 | ||||
| ACEI/ARB | 16 (44) | 19 (61) | +17 | 0.17 | 15 (42) | 14 (42) | 0 | 0.95 |
| BB | 7 (19) | 7 (23) | +4 | 0.75 | 5 (14) | 7 (21) | +7 | 0.26 |
| MRA | 10 (28) | 15 (48) | +20 | 0.08 | 13 (36) | 13 (39) | +3 | 0.78 |
Data are given as n (%). The change in percentages between BL and the EOS is shown.
ACEI, ACE inhibitors; ARB, angiotensin receptor blocker; BB, β receptor blocker; BL, baseline; CHF, chronic heart failure; EOS, end of study; MRA, mineralocorticoid receptor antagonist; PREFER, Palliative advanced homecaRE and heart FailurE caRe.